Forest Laboratories FRX
-
Why Billionaire Carl Icahn Could Target This Substantially Undervalued Biotech
… has made a fortune off of targeting declining biotech companies. He may have failed in taking over the board of Forest Laboratories ( FRX ), but this let down pales in comparison to his success at Biogen ( BIIB ) and Genzyme. Eli Lilly ( LLY …
-
Diamond Hill Small-Mid Cap Fund First Quarter Commentary
… the associated reserves with these projects could be higher than initially expected. Pharmaceuticals company Forest Laboratories , Inc. reported solid fourth quarter results, with sales up 9% year-over-year. Newly launched drugs have …
-
New Morningstar Analyst Report for Forest Laboratories , Inc.
… considerable tax bill if it were to be repatriated. Forest Laboratories is led by chairman and CEO Howard Solomon. We ..... uncertain who will take over upon his departure. Forest Laboratories is a pharmaceutical company focused on in-licensing …
-
Forest Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Forest Laboratories ( FRX ) Q4 2012 Earnings Call April 17, 2012 10:00 am ET Executives Frank J. Murdolo - Vice President of Investor Relations …
-
UPDATE 1-Forest Labs profit tumbles on Lexapro generics
April 17 (Reuters) - Forest Laboratories Inc's quarterly profit plunged 40 percent as the company lost patent protection for its blockbuster Lexapro antidepressant.
-
CORRECTED-Forest Labs profit plunges on Lexapro generics
April 17 (Reuters) - Forest Laboratories Inc's quarterly profit plunged 40 percent as the company lost patent protection for its blockbuster Lexapro antidepressant.
-
Forest Laboratories , Inc. FRX Q4 2012 Earnings Call Transcript
At this time, I would like to welcome everyone to the Forest Laboratories Fiscal 2012 Fourth Quarter Earnings Call of Forest Laboratories . All lines have been placed on mute to prevent any background noise. After the …
-
Likely Approval Spurring Rise Of Forest Laboratories Shares
By Brian L. Wilson : Forest Laboratories ( FRX ) has been rising steadily during the past three months on rumors and speculation that larger pharmaceutical companies are …
-
Forest buys hypertension drug rights from J&J
(Reuters) - Forest Laboratories Inc said on Monday it has acquired the intellectual property rights to hypertension drug Bystolic from Johnson & Johnson's Janssen unit for $357 million cash,...
-
UPDATE 1-Forest buys hypertension drug rights from J&J
April 2 (Reuters) - Forest Laboratories Inc said on Monday it has acquired the intellectual property rights to hypertension drug Bystolic from Johnson & Johnson's Janssen unit for $357 million cash,...